Subcutaneous interferon-β-1a: New formulation

CNS Drugs

Volumn 21, Issue 10, 2007, Pages 871-876

  McKeage, Kate ^a,b   Wagstaff, Antona J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; NEUTRALIZING ANTIBODY;

CLINICAL TRIAL; CYTOPENIA; DEPRESSION; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOGENICITY; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LIVER DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RASH; RELAPSE; REMISSION; REVIEW; SUICIDAL IDEATION; THYROID DISEASE; TREATMENT RESPONSE;

HUMANS; IMMUNITY; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 34548831409     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721100-00006     Document Type: Review

References (26)

1. Noseworthy JH, Lucchinetti C, Rodrigues M, et al. Multiple sclerosis. N Engl J Med 2000; 343 (13): 938-52
2. National Multiple Sclerosis Society. Research/clinical update. National MS Society raises concerns that recent NIH study underestimates number of people with MS in the US [online]. Available from URL: http://www.nationalmssociety. org [Accessed 2007 Jul 4]
3. O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis: an overview. Neurology 2002; 59 Suppl. 3: S1-33
4. Murdoch D, Lyseng-Williamson KA. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in relapsing-remitting multiple sclerosis. Drugs 2005; 65 (9): 1295-312
5. Freedman MS. Disease-modifying drugs for multiple sclerosis: current and future aspects. Expert Opin Pharmacother 2006; 7 Suppl. 1: S1-9
6. Refib® patient exposure. Geneva: Merck Serono International SA, 2007 Jul 13. (Data on file)
7. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis). Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352 (7): 1498-504
8. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59: 1496-506
9. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504
10. Gneiss C, Tripp P, Reichartseder F, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 2006 Dec; 12 (6): 731-7
11. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68 (13): 977-84
12. Jaber A, Baker M. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal 2007; 43: 1256-61
13. Francis GS, Rice GP, Alsop JC. Interferon β-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65 (1): 48-55
14. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs 2005; 19 (3): 239-52
15. Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther 2007 Jun; 29 (6): 1128-45
16. Wagstaff AJ, Goa KL. Recombinant Interferon-β-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis. BioDrugs 1998; 10 (6): 471-94
17. Rebif®: summary of product characteristics. London: Serono Europe Limited, 2003
18. Bellomi F, Muto A, Palmieri G, et al. Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis. New Microbiol 2007; 30 (3): 241-6
19. Brearley C, Jaber A, Bertolino M, et al. Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-β1a: a double-blind, placebo-controlled comparison with the currently available formulation. Int J Clin Pharmacol Ther 2007; 45 (6): 307-18
20. The PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628-36
21. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67 (6): 944-53
22. Scanzillo J, Bennett R, Biancucci P, et al. Product enhancements decrease the incidence of injection site reactions and pain resulting in improved adherence to therapy in patients with multiple sclerosis [abstract plus poster]. 17th Annual Meeting of the European Neurological Society; 2007 Jun 16-20; Rhodes
23. Merck Serono. New formulation of multiple sclerosis treatment Rebif® approved in European Union (media release), 2007 Aug 30 [online]. Available from URL: http://company.merckserono.net [Accessed 2007 Sep 12]
24. Serono International SA. Serono submits new formulation of Rebif® for approval in the United States and in Europe (media release), 2006 Apr 4 [online]. Available from URL: http://company.merckserono.net [Accessed 2007 Sep 12]
25. De Stefano N, Beelke M. A randomised, placebo-controlled, double-blind, multicentre, phase IIIb study assessing efficacy, safety and tolerability of Rebif® new formulation in patients with relapsing-remitting multiple sclerosis [abstract plus poster]. 17th Annual Meeting of the European Neurological Society; 2007 Jun 16-20; Rhodes
26. Kappos L, Freedman M, De Stefano N, et al. REFLEX: a phase III trial to assess the effect of dosing frequency of interferon beta-1a (Rebif®) in delaying conversion of patients with a clinically isolated syndrome to clinically definite multiple sclerosis [abstract no. 409 plus poster]. 17th Annual Meeting of the European Neurological Society; 2007 Jun 16-20; Rhodes